Peripheral T-Cell Lymphoma of the Oral Cavity Diagnosed in the Buccal Mucosa with Relapsed-Refractory Lesion in the Lip: a Rare Case Report

Peripheral T‐cell lymphoma of the oral cavity: A case report

“…Chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is considered the first-line treatment. 3,13 According to Harris et al study, an anthracycline-containing regimen was not as effective as expected like the effect of an nonanthracycline-containing regimen in the treatment of diffuse large B-cell lymphoma, the majority of patients with PTCL or NKTCL, other than ALCL, ALK positive. 17 So further studies should be considered for the effect of anthracyclins.…”

“…In comparison to these studies, our case IHC was positive for CD3 and Ki67 and negative for CD20, also all the other IHC markers were negative in our case study. 2 , 3 , 13 , 14 …”

“…Chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is considered the first‐line treatment. 3 , 13 …”

“…10 Based on previous studies, Immunohistochemistry can help with In comparison to these studies, our case IHC was positive for CD3 and Ki67 and negative for CD20, also all the other IHC markers were negative in our case study. 2,3,13,14 It should be noted that there is a need for further studies to discover new cell markers in addition to current markers. Although it is noted in the literature that CD3 is correlated with a low response to treatment.…”